Kaouthar Khanfir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kaouthar Khanfir has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Abderrahim Zouhair
2 shared publicationsMahmut Ozsahin
2 shared publicationsAdel Kallel
1 shared publicationAgnes Chompret
Department of Radiation Oncology, Institut Gustave Roussy, 94805, Villejuif, France
1 shared publicationAlphonse G. Taghian
1 shared publicationAxel Le Cesne
Department of Radiation Oncology, Institut Gustave Roussy, 94805, Villejuif, France
1 shared publication
Latest Publications
- 1 April 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 82 (5) , 2118-2124
Management of Adenoid Cystic Carcinoma of the Breast: A Rare Cancer Network Study
- 1 April 2012
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 82 (5) , 2118-2124
Management of Adenoid Cystic Carcinoma of the Breast: A Rare Cancer Network Study
- Open Access
- 23 May 2011
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 141 (2122) , w13205
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer
PURPOSE: Chemotherapy (CT) combined with radiation therapy (RT) is the standard treatment for limited disease small-cell lung cancer (LDSCLC). Many questions including RT dose, fractionation, and sequence of RT/CT administration remain controversial. In this paper, we retrospectively assessed the outcome of patients with LDSCLC treated with radiation of at least 50 Gy. METHODS AND MATERIALS: From December 1997 to January 2006, 69 consecutive patients with LDSCLC were treated at our institutions. Treatment consisted of at least 4 cycles of CT, and 3D conformal thoracic RT. The median age was 61 years (range, 37–78 years). Sequential or concomitant CT/RT was given in 47 (68%) and 22 (32%) of the patients, respectively. The median RT dose was 60 Gy. Prophylactic cranial irradiation (PCI) was administered in 47 (68%) patients. RESULTS: With a median follow-up of 36 months (range, 6–107), 16 patients were alive without disease. The median overall survival time was 24 months, with a 3-year survival rate of 29%. The 3-year disease-free survival (DFS) and loco-regional control (LRC) rates were 23% and 60%, respectively. A better DFS was significantly associated with performance status (PS) 0 (p = 0.004), complete response to treatment (p= 0.03), and PCI group (p = 0.03). A trend towards improved overall survival (OS) was observed for patients who underwent PCI (p = 0.07). Patients treated with sequential CT/RT had a better outcome than those treated with concomitant treatment (3-year DFS rate 27% vs. 13%; p = 0.04). However, PCI was delivered more frequently for the sequential group. No significant dose-response relationship was found in terms of LRC. The multivariate analysis showed that complete response to treatment was the only significant factor for OS. CONCLUSION: Complete response to treatment was the most important factor for OS. A better DFS was significantly associated with the PCI group. We did not find a significant difference in outcome between patients receiving doses of 60 Gy or more and patients receiving 60 Gy or less.
- 23 May 2011
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 141 (2122) , w13205
Open AccessSequential or concomitant chemotherapy in limited stage small-cell lung cancer
PURPOSE: Chemotherapy (CT) combined with radiation therapy (RT) is the standard treatment for limited disease small-cell lung cancer (LDSCLC). Many questions including RT dose, fractionation, and sequence of RT/CT administration remain controversial. In this paper, we retrospectively assessed the outcome of patients with LDSCLC treated with radiation of at least 50 Gy. METHODS AND MATERIALS: From December 1997 to January 2006, 69 consecutive patients with LDSCLC were treated at our institutions. Treatment consisted of at least 4 cycles of CT, and 3D conformal thoracic RT. The median age was 61 years (range, 37–78 years). Sequential or concomitant CT/RT was given in 47 (68%) and 22 (32%) of the patients, respectively. The median RT dose was 60 Gy. Prophylactic cranial irradiation (PCI) was administered in 47 (68%) patients. RESULTS: With a median follow-up of 36 months (range, 6–107), 16 patients were alive without disease. The median overall survival time was 24 months, with a 3-year survival rate of 29%. The 3-year disease-free survival (DFS) and loco-regional control (LRC) rates were 23% and 60%, respectively. A better DFS was significantly associated with performance status (PS) 0 (p = 0.004), complete response to treatment (p= 0.03), and PCI group (p = 0.03). A trend towards improved overall survival (OS) was observed for patients who underwent PCI (p = 0.07). Patients treated with sequential CT/RT had a better outcome than those treated with concomitant treatment (3-year DFS rate 27% vs. 13%; p = 0.04). However, PCI was delivered more frequently for the sequential group. No significant dose-response relationship was found in terms of LRC. The multivariate analysis showed that complete response to treatment was the only significant factor for OS. CONCLUSION: Complete response to treatment was the most important factor for OS. A better DFS was significantly associated with the PCI group. We did not find a significant difference in outcome between patients receiving doses of 60 Gy or more and patients receiving 60 Gy or less.
- 30 January 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15 (4) , 1092-1098
Patterns of Failure and Outcome in Patients with Carcinoma of the Anal Margin
To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity. A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed. A surgical excision (close or positive surgical margin in 22 out of 29 patients) was realized before radiotherapy (RT). RT consisted of definitive external beam RT (EBRT) in 36 patients, brachytherapy (BT) alone in two patients, and both BT and EBRT in seven patients. The median total radiation dose was 59.4 Gy (range, 30–74 Gy). The 5-year locoregional control (LRC) rate was 78% [95% confidence interval (CI), 64–93%]. The 5-year disease-specific survival (DSS) and overall survival (OS) rates were respectively 86% (95% CI, 72–99%) and 55% (95% CI, 44–66%). The overall anal conservation rate was 80% for the whole series. There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy. Long-term side effects were observed in 15 patients (33%). Only three patients developed grade 3–4 late toxicity (CTCAE/NCI v3.0). Significant relationship was found between dose, and complication rate (48% for dose ≥59.4 Gy versus 8% for dose < 59.4 Gy; P = 0.03). We conclude that definitive RT and/or BT yield a good local control and disease-specific survival comparable with published data. This study suggests that radiation dose over 59.4 Gy seems to increase treatment-related morbidity.
- 30 January 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15 (4) , 1092-1098
Patterns of Failure and Outcome in Patients with Carcinoma of the Anal Margin
To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity. A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed. A surgical excision (close or positive surgical margin in 22 out of 29 patients) was realized before radiotherapy (RT). RT consisted of definitive external beam RT (EBRT) in 36 patients, brachytherapy (BT) alone in two patients, and both BT and EBRT in seven patients. The median total radiation dose was 59.4 Gy (range, 30–74 Gy). The 5-year locoregional control (LRC) rate was 78% [95% confidence interval (CI), 64–93%]. The 5-year disease-specific survival (DSS) and overall survival (OS) rates were respectively 86% (95% CI, 72–99%) and 55% (95% CI, 44–66%). The overall anal conservation rate was 80% for the whole series. There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy. Long-term side effects were observed in 15 patients (33%). Only three patients developed grade 3–4 late toxicity (CTCAE/NCI v3.0). Significant relationship was found between dose, and complication rate (48% for dose ≥59.4 Gy versus 8% for dose < 59.4 Gy; P = 0.03). We conclude that definitive RT and/or BT yield a good local control and disease-specific survival comparable with published data. This study suggests that radiation dose over 59.4 Gy seems to increase treatment-related morbidity.
- Open Access
- 1 January 2008
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (5) , 973-974
An unusual variant of diffuse retinoblastoma in an adult
(2008). An unusual variant of diffuse retinoblastoma in an adult. Acta Oncologica: Vol. 47, No. 5, pp. 973-974.
- 1 January 2008
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (5) , 973-974
Open AccessAn unusual variant of diffuse retinoblastoma in an adult
(2008). An unusual variant of diffuse retinoblastoma in an adult. Acta Oncologica: Vol. 47, No. 5, pp. 973-974.
- Open Access
- 1 January 2008
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (8) , 1607-1608
Pemetrexed-associated radiation recall dermatitis
(2008). Pemetrexed-associated radiation recall dermatitis. Acta Oncologica: Vol. 47, No. 8, pp. 1607-1608.
- 1 January 2008
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (8) , 1607-1608
Open AccessPemetrexed-associated radiation recall dermatitis
(2008). Pemetrexed-associated radiation recall dermatitis. Acta Oncologica: Vol. 47, No. 8, pp. 1607-1608.